Howe & Rusling Inc. Decreases Stake in Edwards Lifesciences Co. (NYSE:EW)

Howe & Rusling Inc. cut its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 15.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 77,563 shares of the medical research company’s stock after selling 14,055 shares during the quarter. Howe & Rusling Inc.’s holdings in Edwards Lifesciences were worth $5,742,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Crowley Wealth Management Inc. acquired a new stake in Edwards Lifesciences during the 4th quarter worth about $26,000. Millstone Evans Group LLC purchased a new position in shares of Edwards Lifesciences in the fourth quarter worth about $29,000. FSA Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the third quarter worth about $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $30,000. Finally, Roble Belko & Company Inc acquired a new position in Edwards Lifesciences in the 4th quarter worth approximately $46,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In related news, Director Steven R. Loranger sold 5,739 shares of the firm’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the sale, the director now directly owns 60,372 shares in the company, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 62,553 shares of company stock valued at $4,513,064. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Down 0.2 %

NYSE EW opened at $71.12 on Thursday. The business has a fifty day moving average price of $71.45 and a 200 day moving average price of $70.45. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a market cap of $41.81 billion, a P/E ratio of 10.20, a P/E/G ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Research analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Morgan Stanley upped their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Wolfe Research lowered shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. The Goldman Sachs Group lifted their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Citigroup upped their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Finally, Canaccord Genuity Group lifted their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, Edwards Lifesciences has an average rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.